Recro Pharma, Inc. (NASDAQ:REPH) Files An 8-K Other EventsItem 8.01 Other Events.
On August21, 2017, Recro Pharma, Inc. (the “Company”) issued a press release announcing the appointment of Jyrki Mattila, M.D., Ph.D., as Executive Vice President of Business Development of the Company. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 8.01 Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit No. |
Document |
| 99.1 | Press release of Recro Pharma, Inc., dated August 21, 2017. |
Recro Pharma, Inc. ExhibitEX-99.1 2 d436859dex991.htm EXHIBIT 99.1 Exhibit 99.1 Exhibit 99.1 Recro Pharma Appoints Jyrki Mattila as Executive Vice President of Business Development MALVERN,…To view the full exhibit click here
About Recro Pharma, Inc. (NASDAQ:REPH)
Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.
